Open an account

Oncolytics Biotech

ONCY · TORONTO

$0.5023+$0.0021 (+0.42%)TodayMarket closed ·
Prev close $0.5002

About ONCY

The company is headquartered in Calgary, Alberta and currently employs 29 full-time employees.

Employees
28
Headquarters
Calgary, Alberta
Listed
Oct 5, 2001
Sector
Health Care
Industry
Biotechnology
Website
oncolyticsbiotech.com

ONCY key statistics

Market cap
94.18M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.37M
Volume
376.01K
Open price
$0.505
High today
$0.5077
Low today
$0.49
52 Week high
$1.32
52 Week low
$0.4414

Oncolytics Biotech (ONCY) at a glance

Oncolytics Biotech (ONCY) last traded at $0.5023, with a market cap of 94.18M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.49 and $0.5077. The current price is 2.5% above the day's low and 1.1% below its high.

Volume so far is 376.01K shares, below the average of 1.37M shares a day.

Over the past year Oncolytics Biotech has ranged from $0.4414 to $1.32, and now sits 7% of the way up that range.

Oncolytics Biotech met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY25 it reported -$0.1401 per share against an estimate of -$0.0976.

The average analyst price target is $3.32, 560.8% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $3.32
Low
$2.55
Now
$0.5023
High
$3.98

ONCY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 26.9% on average.

  1. Q4 FY23: reported -$0.05 per share against an estimate of -$0.1488
  2. Q1 FY24: reported -$0.09 per share against an estimate of -$0.1091
  3. Q2 FY24: reported -$0.10 per share against an estimate of -$0.1032
  4. Q3 FY24: reported -$0.12 per share against an estimate of -$0.104
  5. Q4 FY24: reported -$0.10 per share against an estimate of -$0.1231
  6. Q1 FY25: reported -$0.08 per share against an estimate of -$0.101
  7. Q2 FY25: reported -$0.07 per share against an estimate of -$0.1077
  8. Q3 FY25: reported -$0.1401 per share against an estimate of -$0.0976

ONCY news

  • Press releasePRNewswire

    Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

  • Press releasePRNewswire

    KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

  • Press releaseGlobe Newswire

    Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs

  • Press releaseGlobe Newswire

    "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

  • Vandana Singh

    Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks

  • Press releaseGlobe Newswire

    The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

  • Press releasePRNewswire

    Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

  • Press releasePRNewswire

    Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.